TWST stock news · Twist Bioscience
Get alerts for TWST
Follow Twist Bioscience (TWST) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TWSTAnthropic's Claude created hundreds of thousands of proteins in just 64 hours to fight scorpion venom.
NeutralTwist Bioscience helped test AI-designed proteins, but they have not been shown to stop venom. The report names no payment or sale for Twist, so its business outlook is unchanged.
Cathie Wood responds to critics, saying comparing ARKK's 15% drop to QQQ's 112% rise isn't fair.
NeutralTwist Bioscience is named among ARKK's healthcare and biotech holdings, but the story gives no new company result or change. It does not change Twist Bioscience's outlook.
Twist Bioscience shares reached a record high of about $192 but then dropped to around $182.
NeutralTwist shares pulled back after reaching a new 52-week high. The article discusses share trading, not a change in the company's business outlook.
On Wednesday, LuxExperience, Alvotech, Twist Bioscience, and other major stocks saw big price jumps.
Good for TWSTA new agreement with Lilly TuneLab expands the company's collaboration footprint in antibody drug discovery.
Despite a short report from Scorpion Capital, Twist Bioscience shares remain strong.
NeutralTwist Bioscience's shares rose sharply after being named an independent evaluator in a significant AI-driven project by Anthropic, despite facing criticism from a short-seller report. This suggests that the market is currently favoring the potential of the partnership over the negative claims made by Scorpion Capital.
Twist Bioscience shares reach a new 52-week peak following selection by Anthropic for a protein design evaluation.
NeutralTwist Bioscience's stock surged to a new 52-week high following its selection by Anthropic as an independent evaluator for a protein design campaign. This development highlights the company's growing involvement in AI-driven drug discovery, which is expected to positively impact its market position and investor sentiment.
Twist Bioscience Corp secures a significant definitive agreement (TWST).
Good for TWSTTwist Bioscience Corp has filed a Form 8-K indicating its entry into a material definitive agreement, which is likely to create new business opportunities and enhance its market position. This development is expected to positively influence investor sentiment and the company's future growth prospects.